BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 94 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,152,677 | -38.9% | 623,525 | +71.3% | 0.00% | -50.0% |
| Q1 2023 | $6,793,845 | -30.5% | 364,086 | -20.0% | 0.00% | -33.3% |
| Q4 2022 | $9,781,262 | +82.3% | 455,366 | +0.3% | 0.00% | +50.0% |
| Q3 2022 | $5,365,000 | -3.9% | 453,877 | +7.3% | 0.00% | 0.0% |
| Q2 2022 | $5,584,000 | -37.3% | 423,021 | -0.7% | 0.00% | -33.3% |
| Q1 2022 | $8,911,000 | +5.8% | 426,177 | +2.8% | 0.00% | +50.0% |
| Q4 2021 | $8,426,000 | -33.5% | 414,484 | -0.7% | 0.00% | -50.0% |
| Q3 2021 | $12,671,000 | +51.5% | 417,510 | +45.1% | 0.00% | +100.0% |
| Q2 2021 | $8,362,000 | -32.9% | 287,752 | -0.3% | 0.00% | -50.0% |
| Q1 2021 | $12,456,000 | -8.8% | 288,605 | -2.4% | 0.00% | 0.0% |
| Q4 2020 | $13,656,000 | +8.6% | 295,574 | +1.9% | 0.00% | -20.0% |
| Q3 2020 | $12,579,000 | -20.2% | 290,117 | -2.4% | 0.01% | -16.7% |
| Q2 2020 | $15,757,000 | +156.9% | 297,245 | +8.3% | 0.01% | +100.0% |
| Q1 2020 | $6,133,000 | – | 274,404 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| APIS CAPITAL ADVISORS, LLC | 40,000 | $836,000 | 1.01% |
| ACT CAPITAL MANAGEMENT, LLC | 20,000 | $418,000 | 0.44% |
| Knoll Capital Management, LLC | 20,000 | $418,000 | 0.26% |
| Artemis Investment Management LLP | 1,428,228 | $29,855,000 | 0.24% |
| Rubric Capital Management LP | 268,528 | $5,615,000 | 0.20% |
| Virtus ETF Advisers LLC | 7,713 | $161,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 107,700 | $2,252,000 | 0.05% |
| PDT Partners, LLC | 28,031 | $586,000 | 0.05% |
| AllSquare Wealth Management LLC | 3,162 | $66,000 | 0.04% |
| Hennion & Walsh Asset Management, Inc. | 35,221 | $736,000 | 0.04% |